E.g., 08/14/2020
E.g., 08/14/2020

Second-Quarter 2020 Business Performance Preannouncement

15 July, 2020

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 July, 2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

27 May, 2020

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch 

06 May, 2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization 

04 May, 2020

First-Quarter 2020 Business Review

24 March, 2020

First of 3 diagnostic tests for  SARS-CoV-2 coronavirus available from bioMérieux

11 March, 2020

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

14 January, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.

bioMérieux – Third-Quarter 2019 Business Review

22 October, 2019

bioMérieux – First-Half 2019 Results

04 September, 2019

Pioneering Diagnostics